An interventional study of percutaneous electrical nerve-field stimulation, PENFS and percutaneous electrical nerve-field stimulation, PENFS (sham device) in Post-Concussion Syndrome, COVID Long-Haul and COVID-19, sponsored by Children's Hospital of Orange County. Recruiting at 1 site in United States. Open to participants aged 11 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Children's Hospital of Orange County · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Post-Concussion Syndrome with a site in United States — 15 open to participants now, 20 under way, 1 of them phase 3. Post-Concussion Syndrome · United States.
Among the 77 studies in Post-Concussion Syndrome with a site in United States, this one is the 9th largest by planned enrollment of the 61 interventional ones that give a count, is one of 8 that started in 2021, is one of 35 with no phase, reaches primary completion later than 6 of the 19 other live ones, and was the 56th registered.
140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.
Browse Post-Concussion Syndrome studies →15 of the 77 studies in Post-Concussion Syndrome with a site in United States are open now. Recruiting first, the newest first:
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Summit Hyperbarics and Wellness · Sites in United States
Ages 18+
Neuroscience Group · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 20–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Post-Concussion Syndrome studies recruiting now, 3 (13%) set no upper age limit and 20 (83%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.
This study: 11 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 15 · Phase 3 2 · Phase 4 2
First in 2004; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is above the median of 52 across 113 interventional studies indexed under Post-Concussion Syndrome.
Median enrollment 40 across the 61 interventional studies, 90 across the 16 observational. Of the 51 that completed or were terminated, 13 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 77 have an industry lead sponsor. The 10 most frequent:
Children's Hospital of Orange County is the lead sponsor of 19 studies on the registry; 11 are open to participants now.
Children's Hospital of Orange County has 2 studies filed under Post-Concussion Syndrome — fewer than ten, so there is no comparison to draw.
8 of the studies in Post-Concussion Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04978571Children's Hospital of Orange CountyPercutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS) | 2026-12 |
| NCT07303933Penn State UniversityFemale Concussion Head Cooling | 2027-01-01 |
| NCT07044596University of Wisconsin, MadisonNon-invasive Stimulation of the Glymphatic System for Slowing Cognitive Decline | 2027-06 |
| NCT07732374Summit Hyperbarics and WellnessLong-Term Outcomes Following HBOT | 2027-06-18 |
| NCT04760899University of IowaCerebellar TDCS for SRPCS Treatment | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 77 studies in Post-Concussion Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the effect of Auricular Percutaneous Electrical Nerve Field Stimulation (a Neurostim device) on children with pain and Post Concussion symptoms.
An additional purpose of this study is to demonstrate that PENFS improves functioning in children with post Covid-19 symptoms.
The purpose of this study is to test the effect of Auricular Percutaneous Electrical Nerve Field Stimulation (a Neurostim device) on children with pain and Post Concussion symptoms. Patient will be offered a Neurostim device. This device is placed on the outer ear through tiny needles. Since this is a randomized trial, patients may receive an active (experiment) or nonactive (control) Neurostim device. However, the nonactive control Neurostim device group will be given the option to receive an active device after the initial study procedures. The experiment group may be in this study up to 8 weeks and the control group may be in this study up to 12 weeks. The control group will have 4 additional weeks due to the transition to an active device following the first 8 weeks. The device is worn weekly for 4 weeks. Each device is worn for 5 consecutive days for the full 24 hours. The participant will be able to easily take the device off on the 6th day. Study procedures include: Neurological testing- a balance test and computerized neurological standard testing, Cardiology testing- electrocardiogram for heart rate variability (heart electrical pulse test), a pupilometer (eye) test, and parent/child questionnaires. You may benefit from this research, but there is no guarantee that being in this study will help you.
Patients in the COVID arm will be offered 6 placements of Neurostim devices. This device is placed on the outer ear through tiny needles. Patients in this arm will not be randomized, all patients will receive active devices. This group will be in the study for up to 10 weeks. The device is worn weekly for 6 weeks. Each device is worn for 5 consecutive days for the full 24 hours. The patient will be able to remove the device on the 6th day. Study procedures include: Neurological testing called Cognigram to measure cognitive functioning and parent/child questionnaires. After 6 weeks of device placements, parent and child will complete a 1-week and 1-questionnaires. You may benefit from this research, but there is no guarantee that being in this study will help you.
Concussion:
Inclusion Criteria:
Exclusion Criteria:
COVID:
Inclusion Criteria
You cannot participate in this study if you meet the following exclusion criteria:
Patients in this group will receive the active devices for the initial 4 study weeks.
Device: percutaneous electrical nerve-field stimulation, PENFS
Patients in this group will receive the sham devices for the initial 4 study weeks. However, they will be offered the 4 active devices after.
Device: percutaneous electrical nerve-field stimulation, PENFS (sham device)
Patients in this group will receive the active devices for the 6 study weeks.
Device: percutaneous electrical nerve-field stimulation, PENFS (COVID active device)
A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.
A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
Immediate Post-Concussion Assessment
With the Immediate Post-Concussion Assessment, percentiles indicate functioning assessment after a concussion. Having a higher score on this assessment implies having a worse outcome assessment.
Time frame: 8 weeks
Post-Concussion Symptom Scale
Post Concussion Symptom Scale- a 22 item questionnaire, rated on a 0-6 scale. Having a higher score indicates having worse symptom assessment.
Time frame: 8 weeks
Balance Error Scoring Symptom
Balance Error Scoring Symptom- a balance test conducted in person. Patient is asked to do a 3 poses on the floor and 3 poses standing on a foam and asked to stand still. The amount of errors will be counted for the times the patient moves. The higher the errors, means patient does not have a well-balance.
Time frame: 8 weeks
COGNIGRAM
COGNIGRAM is a test prescribed by clinicians to measure cognitive function.
Time frame: 10 weeks
Abdominal Pain Index
4 item to rate abdominal pain. Higher score indicates having worse outcome.
Time frame: 8 weeks
Baxter Animated Retching Faces Nausea Scale
rate on a 1-10 scale level of nausea. Higher score indicated feeling worse.
Time frame: 8 weeks
Children's Somatization inventory
23 item to rate symptoms, higher score indicates worse symptoms
Time frame: 8 weeks
Functioning disability inventory
15 item, asking on functioning, higher score indicated worse outcome.
Time frame: 8 weeks
Patient-Reported Outcomes Measurement Information System- Anxiety
8 item questionnaire asking on anxiety level. Higher score indicates worse outcome.
Time frame: 8 weeks
Patient-Reported Outcomes Measurement Information System- Depression
8 item asking on depression, higher score indicated worse outcome
Time frame: 8 weeks
Patient-Reported Outcomes Measurement Information System-Global health scales
7-item asking on general health, lower score indicates worse outcome
Time frame: 8 weeks
Covid-19 questionnaire
40-item asking Covid related symptoms and history.
Time frame: 10 weeks
Orthostatic Vitals
numerical number that determines blood pressure. Having a high blood pressure indicates worse outcome. Reading will be done by a provider.
Time frame: 8 weeks
Electrocardiography
Heart rate measurement- a recording of electrical signal from the heart to check for heart conditions. Reading will be done by a provider.
Time frame: 8 weeks
Pupillometry
Pupillometry: An eye assessment to measure pupil size and reactivity, reading will be done by a provider
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2021 (actual). Primary completion is estimated for Dec 2026, 70 months after the start.
Of 54 non-industry interventional studies with no phase under Post-Concussion Syndrome, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's planned 70 months is above that.
Counting every sponsor, half of 56 studies reached it within 40 months; a quarter within 23 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital of Orange County